At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of ENDEAVOR, a randomised, open-label, phase 3 trial comparing carfilzomib plus dexamethasone versus bortezomib plus dexamethasone in patients with relapsed multiple myeloma.
ENDEAVOR: Phase 3 trial comparing carfilzomib versus bortezomib in relapsed multiple myeloma
26th August 2015
Oncology
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given